Dollar Amounts
USD (Millions)
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Assets | $2,028 | $2,263 | $2,295 | $2,639 | $2,704 |
| Liabilities | $646 | $700 | $593 | $672 | $635 |
| Equity | $1,381 | $1,563 | $1,702 | $1,967 | $2,069 |
Balance sheet data in USD (millions)
Doing some research...
Edwyn
Over the past five years, BIO-TECHNE Corp has shown consistent growth in its financial position. Total assets have steadily increased from $2.03 billion in 2020 to $2.70 billion in 2024, reflecting a strong upward trajectory. This growth indicates the company's ability to expand its operations, invest in new opportunities, and potentially generate higher revenues. Simultaneously, total liabilities have also increased, although at a slower rate compared to assets. Liabilities rose from $646.40 million in 2020 to $635.02 million in 2024. This suggests that the company has been able to manage its debt levels effectively while growing its asset base, which is a positive sign for investors and creditors alike. Stockholders' equity has shown significant growth, climbing from $1381.19 million in 2020 to $2068.85 million in 2024. This increase indicates that the company's shareholders have seen their ownership stake in the company rise substantially over the period. The strengthening equity position can be seen as a sign of the company's financial health and long-term sustainability. Overall, BIO-TECHNE Corp's financial position appears robust, with a healthy balance sheet and a positive growth trend that aligns well with industry expectations.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.